With an IPO date in April 2023, this consumer discretionary stock is ready to take on the open market with a $17 million IPO. Let’s see why this should be on your top watch list…
This Apparel Powerhouse is Looking Stylish, Here’s Why…
With remarkable growth and strategic partnerships, this company could be one of the most promising brands to emerge in the apparel and wellness markets…
Parkinson’s Treatment FDA Approval Solidifies Massive Upside Potential
After the FDA delivered an approval to this low float biotech, its already mammoth potential grew even bigger. In line with the primed nano-cap market, see why this company is a potential goldmine.
Orphan Drug Designation and New Patent Means Immense Potential For This Micro-Float
This Orphan Drug Designated micro-float was just granted it’s 8th Patent after bouncing off it’s 52-week low, prompting a Wall St. Analyst to assign a +500% price target.
Insiders Are Buying This Medical Tech Goldmine And It’s Breaking Out
This recent medical device stock’s moderate float breakout presented mammoth potential and insiders are amassing shares. Get your eyes on this one early!
Huge Break-through Treatment Leading To Huge Break-Out Profits?
An answer to myeloid leukemia could be imminent with over 773 percent potential upside, according to an HC Wainwright Analyst. Take a moment to learn why Actinium Pharmaceuticals might be behind biotech’s next generational leap forward.
Cannabis Company Set to Explode in 2022
The burgeoning cannabis industry is in the middle of an explosion, led at least in part by a company that aims to be a figurehead of the cannabis industry. With the lowest production cost in the industry, this is a stock to watch.